000256776 001__ 256776
000256776 005__ 20190619220044.0
000256776 0247_ $$2doi$$a10.5075/epfl-irgc-256776
000256776 037__ $$aREP_WORK
000256776 245__ $$aWorkshop Report: The Economics of Precision Medicine
000256776 260__ $$bEPFL IRGC$$c2018-07-18
000256776 269__ $$a2018-07-18
000256776 300__ $$a32
000256776 336__ $$aReports
000256776 500__ $$aThis publication should be cited as: EPFL IRGC (2018). The Economics of Precision Medicine. A Risk-Governance Perspective. Lausanne: EPFL International Risk Governance Center.
000256776 520__ $$aThis report from a multi-stakeholder workshop on the ‘Economics of precision medicine’ addresses the issues of cost-effectiveness, as well as the need to revise how economic and social value can be valorised and financed, and to develop new business models for fundamentally personalised gene therapies with high up-front costs.
000256776 6531_ $$aIRGC
000256776 6531_ $$aprecision medicine
000256776 6531_ $$aeconomics
000256776 6531_ $$acost-effectiveness
000256776 700__ $$g180075$$aNursimulu, Anjali$$0244316
000256776 700__ $$0254419$$aFlorin, Marie-Valentine$$g228955
000256776 710__ $$aIRGC
000256776 8560_ $$fanca.rusu@epfl.ch
000256776 8564_ $$uhttps://infoscience.epfl.ch/record/256776/files/The%20economics%20of%20precision%20medicine.pdf$$zFinal$$s1439596
000256776 909C0 $$xU12705$$manca.rusu@epfl.ch$$zBorel, Alain$$0252602$$yApproved$$pIRGC
000256776 909CO $$qGLOBAL_SET$$pDOI$$preport$$ooai:infoscience.epfl.ch:256776
000256776 960__ $$aanca.rusu@epfl.ch
000256776 961__ $$apierre.devaud@epfl.ch
000256776 973__ $$aEPFL$$sPUBLISHED$$rREVIEWED
000256776 980__ $$aREP_WORK
000256776 981__ $$aoverwrite